HLN
Haleon plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.60
−2.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.4B | 11.0B | 11.2B | 11.3B | 10.9B |
| Cost of Revenue | 6.8B | 3.8B | 4.3B | 4.3B | 4.3B |
| Gross Profit | 12.6B | 7.0B | 6.9B | 7.0B | 6.6B |
| Operating Expenses | |||||
| R&D Expense | 539.6M | 308.1M | 298.0M | 311.0M | 300.0M |
| SG&A Expense | 7.7B | 4.4B | 4.3B | 4.3B | 4.0B |
| General & Admin Expense | — | 4.4B | 4.5B | 2.3B | 2.0B |
| Selling & Marketing Expense | — | — | (119.0M) | 2.0B | 2.0B |
| Other Expenses | 19.5M | (243.3M) | 111.0M | 366.0M | 415.0M |
| Total Operating Expenses | 8.2B | 4.4B | 4.7B | 5.0B | 4.8B |
| Cost and Expenses | 15.0B | 8.6B | 9.0B | 9.3B | 9.0B |
| Operating Income (EBIT) | 4.4B | 2.4B | 2.2B | 2.0B | 1.8B |
| Non-Operating | |||||
| Interest Income | 65.1M | 76.3M | 55.0M | 14.0M | 69.0M |
| Interest Expense | 510.6M | 332.5M | 394.0M | 414.0M | 347.4M |
| Net Interest Income | (445.6M) | (256.3M) | (339.0M) | (400.0M) | (278.4M) |
| Other Non-Op Income/Expense | (654.0M) | (260.0M) | (296.0M) | (368.0M) | (207.0M) |
| Non-Operating Income (excl Interest) | (21.0M) | — | (112.0M) | (46.0M) | (71.0M) |
| EBT (Pre-Tax Income) | 3.7B | 2.2B | 1.9B | 1.6B | 1.6B |
| Income Tax Expense | 889.8M | 461.7M | 435.0M | 517.0M | 499.0M |
| Bottom Line | |||||
| Net Income | 2.8B | 1.6B | 1.4B | 1.0B | 1.1B |
| Earnings from Cont. Ops | 2.9B | 1.6B | 1.5B | 1.1B | 1.1B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.8B | 1.6B | 1.4B | 1.0B | 1.1B |
| Per Share | |||||
| Basic EPS | $0.63 | $0.36 | $0.32 | $0.24 | $0.24 |
| Diluted EPS | $0.63 | $0.36 | $0.32 | $0.24 | $0.24 |
| Revenue Per Share | $4.36 | $2.46 | $2.46 | $2.44 | $2.35 |
| Shares | |||||
| Basic Shares Outstanding | 4.4B | 4.5B | 4.6B | 4.6B | 4.6B |
| Diluted Shares Outstanding | 4.5B | 4.5B | 4.6B | 4.6B | 4.6B |
| Profitability Metrics | |||||
| EBITDA | 5.0B | 2.9B | 2.5B | 2.4B | 2.2B |
| D&A | 586.6M | 352.1M | 196.0M | 309.0M | 287.0M |
| EBIT | 4.4B | 2.5B | 2.3B | 2.0B | 1.9B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026